KDR and cervical carcinoma: Clinical studies, represented by GOG240, have demonstrated that the use of bevacizumab, an agent that targets VEGFR, in combination with chemotherapy significantly improves progression free survival (PFS) and overall survival (OS) in patients with advanced cervical cancer (31).